Scientists at York University have uncovered a genetic process that may allow ovarian cancer to resist chemotherapy.
They studied a tiny strand of our genetic makeup known as a MicroRNA, involved in the regulation of gene expression. Cancer occurs when gene regulation goes haywire.
"Ovarian cancer is a very deadly disease because it`s hard to detect," says biology professor Chun Peng, who co-authored the study. By the time it`s diagnosed, usually it is in its late stages. And by that point there`s really no way to treat the disease. Even when the disease is discovered in its early stages, chemotherapy doesn`t always work," she says.
Peng was among a team of researchers that discovered a receptor, ALK7, that induces cell-death in epithelial ovarian cancer cells. They have now discerned that microRNA 376c targets this crucial receptor, inhibiting its expression and allowing ovarian cancer cells to thrive.
"Our evidence suggests that microRNA 376c is crucial to determining how a patient will respond to a chemotherapeutic agent," says Peng. "It allows cancer cells to survive by targeting the very process that kills them off," she says.
In examining tumours taken from patients who were non-responsive to chemotherapy, researchers found a higher expression of microRNA 376c and a much lower expression of ALK7.
Peng believes that this research is a step towards being able to make chemotherapy drugs more effective in the treatment of the disease.
The article, "MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance," was published in the Journal of Cell Science.